24-Hour Urinary Sodium and Potassium Excretion and Cardiovascular Risk.

N Engl J Med

From the Departments of Epidemiology (Y.M., Q.S., G.C.C., M.W., E.B.R., J.E.M., W.C.W., A.H., N.R.C., F.B.H.) and Nutrition (Q.S., C.Y., E.B.R., W.C.W., F.B.H.), Harvard T.H. Chan School of Public Health, and the Channing Division of Network Medicine, the Department of Medicine (Q.S., G.C.C., E.B.R., J.E.M., W.C.W., F.B.H.), Renal Division, the Department of Medicine (G.C.C.), and the Division of Preventive Medicine (J.E.M., N.R.C.), Brigham and Women's Hospital and Harvard Medical School - all in Boston; the Wolfson Institute of Population Health, St. Bartholomew's Hospital and the London School of Medicine and Dentistry, Queen Mary University of London, London (F.J.H., G.A.M.); the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (L.M.K., S.J.L.B., R.T.G.); and the Departments of Medicine, Community Health Sciences, and Physiology and Pharmacology, O'Brien Institute of Public Health and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada (N.R.C.C.).

Published: January 2022

Background: The relation between sodium intake and cardiovascular disease remains controversial, owing in part to inaccurate assessment of sodium intake. Assessing 24-hour urinary excretion over a period of multiple days is considered to be an accurate method.

Methods: We included individual-participant data from six prospective cohorts of generally healthy adults; sodium and potassium excretion was assessed with the use of at least two 24-hour urine samples per participant. The primary outcome was a cardiovascular event (coronary revascularization or fatal or nonfatal myocardial infarction or stroke). We analyzed each cohort using consistent methods and combined the results using a random-effects meta-analysis.

Results: Among 10,709 participants, who had a mean (±SD) age of 51.5±12.6 years and of whom 54.2% were women, 571 cardiovascular events were ascertained during a median study follow-up of 8.8 years (incidence rate, 5.9 per 1000 person-years). The median 24-hour urinary sodium excretion was 3270 mg (10th to 90th percentile, 2099 to 4899). Higher sodium excretion, lower potassium excretion, and a higher sodium-to-potassium ratio were all associated with a higher cardiovascular risk in analyses that were controlled for confounding factors (P≤0.005 for all comparisons). In analyses that compared quartile 4 of the urinary biomarker (highest) with quartile 1 (lowest), the hazard ratios were 1.60 (95% confidence interval [CI], 1.19 to 2.14) for sodium excretion, 0.69 (95% CI, 0.51 to 0.91) for potassium excretion, and 1.62 (95% CI, 1.25 to 2.10) for the sodium-to-potassium ratio. Each daily increment of 1000 mg in sodium excretion was associated with an 18% increase in cardiovascular risk (hazard ratio, 1.18; 95% CI, 1.08 to 1.29), and each daily increment of 1000 mg in potassium excretion was associated with an 18% decrease in risk (hazard ratio, 0.82; 95% CI, 0.72 to 0.94).

Conclusions: Higher sodium and lower potassium intakes, as measured in multiple 24-hour urine samples, were associated in a dose-response manner with a higher cardiovascular risk. These findings may support reducing sodium intake and increasing potassium intake from current levels. (Funded by the American Heart Association and the National Institutes of Health.).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153854PMC
http://dx.doi.org/10.1056/NEJMoa2109794DOI Listing

Publication Analysis

Top Keywords

potassium excretion
20
cardiovascular risk
16
sodium excretion
16
24-hour urinary
12
sodium intake
12
sodium
10
excretion
10
urinary sodium
8
sodium potassium
8
24-hour urine
8

Similar Publications

Background: The primary prevention of atrial fibrillation (AF), which increases mortality through complications including stroke and heart failure, is important. Excessive salt intake and low potassium intake are risk factors for cardiovascular disease; however, their association with AF remains inconclusive. This study investigated the association between sodium- and potassium-related urinary markers and AF prevalence.

View Article and Find Full Text PDF

Distal renal tubular acidosis (dRTA) is a significant clinical expression of Sjögren's syndrome (SS). While SS-related dRTA is traditionally linked to impaired H-ATPase, we report a unique case demonstrating selectively decreased anion exchanger 1 (AE1) expression with preserved H-ATPase expression. A 16-year-old girl with SS presented with muscle weakness, difficulty in ambulation, and severe hypokalemia.

View Article and Find Full Text PDF

Agreement between methods to assess potassium intake in patients with chronic kidney disease.

Clin Nutr ESPEN

January 2025

Post Graduation Program in Medical Science, Rio de Janeiro State University, Rio de Janeiro, 20550-900, Brazil; Department of Applied Nutrition, Nutrition Institute, Rio de Janeiro State University, Rio de Janeiro, 20550-900, Brazil. Electronic address:

Background & Aims: In the general population, 24-hour urine potassium excretion is considered the reference standard for estimating potassium intake. However, its agreement with food records and spot urine collections in adults living with chronic kidney disease (CKD) is not well-established. Given the risk of hyperkalemia related to changes in renal potassium handling, understanding if this reference standard is appropriate for the CKD population is important.

View Article and Find Full Text PDF

Background: Adjusting dietary potassium intake based on 24-hour urinary potassium excretion is the primary method of preventing hyperkalemia. Currently, there is no accurate and convenient method for calculating maximum 24-hour urinary potassium excretion in kidney failure without replacement therapy patients. We developed and validated two new models to assess the upper limit of dietary potassium consumption in this high-risk cohort, using the maximum 24-hour urinary potassium excretion as a proxy.

View Article and Find Full Text PDF

Even in current guideline-directed medical therapy, including recently introduced vasopressin type 2 receptor antagonist tolvaptan, congestion has not been resolved in patients with heart failure. Kampo medicine goreisan has been receiving considerable attention as an additional therapy for patients who are refractory to conventional diuretics therapy, including tolvaptan. However, the impact of goreisan on urine electrolytes remains uncertain.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!